Why choose Beacon Biomedical's Ltd solutions?
Beacon Biomedical's laboratory developed test (LDT) solutions help primary care providers screen their patients for the presence of undiagnosed cancer to improve their chances of survivability.
What are analysts'target prices for Biogen's stock?
31 analysts have issued 1-year target prices for Biogen's stock. Their forecasts range from $200.00 to $400.00. On average, they anticipate Biogen's share price to reach $291.40 in the next twelve months.
Where can I buy Biogen shares?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biogen's stock price today?
What are the best value biotech stocks to buy?
Best Value Biotech Stocks Price ($) Market Cap ($B) 12-Month Trailing P/E Ratio XBiotech Inc. ( XBIT) 19.36 0.6 1.2 Catalyst Pharmaceuticals Inc. ( CPRX) 3.70 0.4 5.5 Innoviva Inc. ( INVA) 11.63 1.2 5.8
Should I buy or sell Biogen stock right now?
28 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 1...
What is Biogen's stock price forecast for 2022?
28 analysts have issued twelve-month price targets for Biogen's shares. Their forecasts range from $185.00 to $500.00. On average, they expect Biog...
How has Biogen's stock performed in 2022?
Biogen's stock was trading at $239.92 at the start of the year. Since then, BIIB stock has decreased by 17.7% and is now trading at $197.50. View...
When is Biogen's next earnings date?
Biogen is scheduled to release its next quarterly earnings announcement on Thursday, July 28th 2022. View our earnings forecast for Biogen .
How were Biogen's earnings last quarter?
Biogen Inc. (NASDAQ:BIIB) announced its earnings results on Tuesday, May, 3rd. The biotechnology company reported $3.62 EPS for the quarter, missin...
What guidance has Biogen issued on next quarter's earnings?
Biogen issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share (EPS) guidance of $14.25-$16....
Who are Biogen's key executives?
Biogen's management team includes the following people: Mr. Michel Vounatsos , CEO & Director (Age 60, Pay $4.51M) ( LinkedIn Profile ) Mr. Mich...
What is Michel Vounatsos' approval rating as Biogen's CEO?
186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com . Michel Vounatsos has an approval rating of 86% among Biogen's employees.
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN) , Gilead Sciences (GILD) , Vertex Pharmaceuticals (VRTX) , Regeneron Pharmaceuti...
When did Biogen repurchase its stock?
Biogen announced that its Board of Directors has approved a share repurchase program on Monday, December 23rd 2019 , which authorizes the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase shares of its stock through open market purchases. Shares repurchase programs are typically an indication that the company's board believes its shares are undervalued.
How much is Biogen's 2021 earnings?
Biogen updated its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share (EPS) guidance of $18.850-$19.350 for the period, compared to the Thomson Reuters consensus EPS estimate of $18.610. The company issued revenue guidance of $10.80 billion-$10.90 billion, compared to the consensus revenue estimate of $10.76 billion.
What is MarketBeat community ratings?
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote “Outperform” if you believe BIIB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is the biogen symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How much did Biogen make in the quarter?
The biotechnology company reported $5.68 EPS for the quarter, beating the consensus estimate of $4.55 by $1.13. The biotechnology company earned $2.78 billion during the quarter, compared to the consensus estimate of $2.61 billion.
What is the official website for Biogen?
The official website for Biogen is www.biogen.com.
What is the P/E ratio of Biogen?
The P/E ratio of Biogen is 24.68, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.97.
What is the return on biotech stocks in 2021?
During the past year, biotech stocks, as represented by the iShares Biotechnology ETF ( IBB ), have posted a total return of 27.0%, below the Russell 1000's total return of 35.1% as of Sept. 16, 2021. 1 All data below are as of Sept. 16, 2021.
What are the best biotech stocks?
Best Value Biotech Stocks 1 Agios Pharmaceuticals Inc.: Agios is a pharmaceutical company developing drug treatments for genetically defined diseases such as hemolytic anemias and sickle cell disease. The company reported net income of $1.9 billion for Q1 2021 versus a loss in Q1 2020. This figure was impacted by the sale of Agios' oncology portfolio to Servier Pharmaceuticals LLC in Q1 2021. 2 2 Sage Therapeutics Inc.: Sage Therapeutics creates treatments for central nervous system disorders including schizophrenia and major depressive disorder. In Q1 2021, the company reported positive trial developments in its SAGE-718, a drug with the potential to be used in the treatment of Huntington disease. 3 3 Innoviva Inc.: Innoviva is a healthcare-focused asset management company that holds a portfolio of royalties from a variety of pharmaceuticals.
What is Sage Therapeutics?
Sage Therapeutics Inc.: Sage Therapeutics creates treatments for central nervous system disorders including schizophrenia and major depressive disorder. In Q1 2021, the company reported positive trial developments in its SAGE-718, a drug with the potential to be used in the treatment of Huntington disease. 3.
What is biotechnology industry?
The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. These products must go through rigorous, costly, and time-consuming trials before potentially obtaining approval from the U.S. Food and Drug Administration (FDA).
What is Ocugen Inc?
Ocugen Inc.: Ocugen is a biopharmaceutical company focusing on therapies for blindness and other retinal diseases. The company's net loss widened dramatically as research and development expenses soared compared to the same quarter a year earlier. It posted no revenue. Despite this, partner Bharat Biotech of India posted positive Phase 3 clinical trial results for COVAXIN, the company's COVID-19 vaccine. In those trials, the drug demonstrated 77.8% efficacy against overall COVID-19 disease, 93.4% efficacy against severe COVID-19 disease, and 65.2% efficacy against the Delta variant. 7
What is Cogent Biosciences?
is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. more
What is Bionano Genomics?
Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The firm engages in the development and marketing of Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA. more
What is Actinium Pharmaceuticals?
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel targeted therapies known as Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell killing ability of radiation. The company was founded in 2002 and is headquartered in New York, NY. more
What is Viracta Therapeutics?
Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision onc ology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA. more
Recently Viewed Tickers
Visit a quote page and your recently viewed tickers will be displayed here.
Biogen Inc
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases.